Introduction
Aryl hydrocarbon receptor (Ahr) is a ligand-activated transcription factor that mediates numerous cellular responses to toxins and plays critical modulatory roles in various immune cells during innate and adaptive immune responses. Ahr was originally investigated as a receptor for environmental contaminants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). More recently, studies have examined Ahr in immune cells including T cells and antigen-presenting cells including dendritic cells (DCs) and macrophages. The balance between T h 17 cells and the other T-cell subsets is particularly critical to ensure that a specific T-cell subset does not predominate and-together with other transcriptional changes-cause disorders associated with aberrant cytokine production.
One approach has been to specifically delete Ahr in macrophages or T cells. Mice lacking Ahr in macrophages or T cells are used as models of inflammatory and autoimmune diseases, including LPS-induced shock and collagen-induced arthritis (CIA). In addition, Ahr has been investigated in experimental autoimmune encephalomyelitis (EAE) and dextran sulfate sodium (DSS)-induced colitis, among other disease models. In this review, we discuss the roles of Ahr in immune and non-immune cells, including contributions to various animal models of disease. Importantly, the signaling cascades and biochemical processes associated with Ahr are promising avenues to modulate immune responses in the clinic.
Ahr signaling pathways
Ahr is a ligand-activated member of the Per-Arnt-Sim family of basic helix-loop-helix transcription factors. Normally, Ahr forms cytoplasmic complexes with various proteins, such as heat shock protein 90, Ahr-interacting protein and p23 (1) (2) (3) . Binding of Ahr to a xenobiotic ligand, such as TCDD, induces translocation of the Ahr complex into the nucleus, where it binds Ahr nuclear translocator (Arnt). In the nucleus, Ahr-Arnt heterodimers bind xenobiotic-responsive elements (XREs) in the promoters of responsive genes, including those encoding members of the cytochrome P450 family (4) (5) (6) (7) . Ahr repressor-a marker of Ahr activation-attenuates Ahr signaling (8) .
Ahr is involved in cell proliferation, differentiation and cytokine secretion. Furthermore, several inflammatory response-related genes contain multiple potential XRE boxes in upstream sequences (9) . It is likely that the different distributions of XREs contribute to the transcriptional regulation of various immune activities following Ahr activation. Yet, few studies have examined the precise roles of Ahr and XREs in these processes. Of note, the Ahr reportedly serves not only as a transcription factor but also as part of a ligand-dependent E3-type ubiquitin ligase complex to regulate selective protein degradation. Protein ubiquitination involves a ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin protein ligase (E3), which acts as a bridge between E2 and the substrate (10, 11). Ohtake et al. (10, 11) found that Ahr activation by such ligands as 3-methylcholanthrene (3MC) and β-naphthoflavone decreased protein levels of endogenous estrogen receptor (ER)α, ERβ and androgen receptor (AR). Ligand-bound Ahr assembles into the CUL4B-based atypical E3 ubiquitin ligase complex CUL4BAhr, which includes CUL4B, DNA-binding protein 1, Rbx1, subunits of the 19S regulatory particle of the 26S proteasome, Arnt and transducin β-like 3 (10, 11) . Ahr has E3 ubiquitin ligase activity both in vitro and in vivo (11) . For instance, reconstituted in vitro ubiquitination assays have shown that the E3 ubiquitin ligase activity of CUL4BAhr for ERα is dependent on 3MC and not on E2 (10, 11) . On the other hand, degradation of ERα or AR in the uterus and prostate can be induced by Ahr activation but is not observed in Ahr-deficient (Ahr −/− ) mice (12, 13) . In addition, following activation of TLRs, Ahr interacts with proteins involved in NF-κB signaling. Ahr activation also leads to proto-oncogene expression via 'cross-talk' with the p38 MAPK signaling pathway (14) . For example, Ahr activates p38-MAPK signaling to regulate the expression of c-jun, which encodes an AP-1 subunit, by the Ahr ligand TCDD (14) .
Ahr is activated in immune and/or cancer cells by many exogenous xenobiotic ligands, including TCDD, 3MC, bezo[a]pyrene (BaP), and such endogenous ligands as 6-formylindolo [3,2-b] carbazole (FICZ), Kynurenine (Kyn) and 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) (15) (16) (17) (18) . Receptor affinity and the degree of activation likely reflect the planarity, aromaticity and hydrophobicity of the ligand (15) .
Ahr in T cells and autoimmune diseases
Three separate laboratories reported that Ahr regulates the differentiation of IL-17-producing T (T h 17) and T reg cells (19) (20) (21) . Using DNA microarrays, Kimura et al. (19) showed that Ahr is expressed under T h 17 cell-polarizing conditions characterized by IL-6 and TGF-β but not in response to either cytokine alone. IL-6 inhibits TGF-β-induced Foxp3 + T reg cell differentiation and initiates T h 17 cell development; these effects shift the balance between T h 17 and T reg cells and contribute to the pathogenesis of several animal models of autoimmune diseases, including EAE and CIA (19) (20) (21) (22) (23) (24) . Ahr −/− naive T cells exposed to IL-6 and TGF-β in vitro fail to differentiate into T h 17 cells owing to a lack of inhibitory interactions between Ahr and negative regulators of T h 17 cell differentiation (e.g. Stat1 and Stat5) and/or binding of Ahr to the IL-17 promoter (19, 25, 26) . An overview of Ahr in T h 17, T reg and type 1 T regulatory (T r 1) cell development can be found in Figs 1 and 2 .
Results from several studies on the role of Ahr in experimental autoimmune diseases have been summarized in Table 1 . These results, however, do not entirely agree perhaps owing to differences in the examined ligands, cell types and/or regulatory signaling pathways. TCDD and FICZ promote T reg and T h 17 cell differentiation in vitro (19) . Veldhoen et al. (20) demonstrated that activating Ahr with FICZ enhances T h 17 cell development and promotes the development of EAE. On the other hand, Quintana et al. (21) reported that the effects of Ahr on T reg and T h 17 cell differentiation are ligand specific; FICZ and TCDD promote and inhibit EAE development, respectively. Differences in the molecular stabilities of TCDD and FICZ may explain the disparate results associated with these Ahr ligands. The affinity of the rapidly metabolized FICZ for Ahr is higher than that of TCDD. On the other hand, TCDD also shows a high affinity for Ahr but is not metabolized. Ahr is less sensitive to Kyn than TCDD or FICZ, which may reflect the weakly basic aromatic amine in Kyn (Fig. 3) . Thus, Kyn is used experimentally at millimolar concentrations compared with nanomolar for TCDD.
The different stabilities of these ligands may be caused by different enzymatic modifications during metabolism. For instance, Mezrich et al. (28) found that FICZ and Kyn differently affect T reg cell differentiation and hypothesized that Kyn but not FICZ may be modified by Ahr-induced cytochrome P450 enzymes. To elucidate the intracellular mechanisms and effects of each Ahr ligand, the metabolism of each ligand should be examined in detail.
Contrary to findings from Veldhoen et al. (20) showing that Ahr −/− mice develop less severe EAE, Quintana et al. (21, 29) showed that Ahr d mice, which express a low-affinity Ahr variant caused by a mutation in the ligand-binding site, developed more severe EAE and a reduced frequency of Foxp3 + Treg cells in several tissues of Ahr d mice. We recently reported that Ahr −/− mice are resistant to the development of CIA probably because of reduced T h 17 cell differentiation (30) . These findings indicate that a lack of Ahr and a low-affinity variant of Ahr (Ahr d ) result in contrasting outcomes in various models of autoimmune diseases (20, 21, 29, 30) . Ahr d mice express a 104-kDa receptor with a ligand affinity that is 10-to 100-fold lower than that of the receptor produced by C57BL/6J mice. In a previous study, we found that the frequency of Foxp3 + T reg cells generated from naive T cells in the presence of TGF-β is mildly increased by Ahr ligands including TCDD and FICZ in vitro (19) . On the other hand, the role of Ahr in T reg cell development is still controversial (31) (32) (33) . There is a possibility that Treg cells are proportionally overrepresented in the CD4 T-cell population induced by TCDD due to minimal receptor expression and they are likely to escape death by overstimulation (32) . In this case, thus, whether the absolute number or percentage of T reg cells is increased needs further consideration (32) . Because the balance between T h 17 and T reg cells is critical, understanding the conditions under which Ahr induces T h 17 or T reg cell development during autoimmune disease development may shed light on the precise roles of Ahr. Veldhoen et al. (20) and Nakahama et al. (30) showed that Ahr deficiency in EAE and CIA disease models resulted in fewer T h 17 cells and no effects on Foxp3 + Treg cells, respectively. Ahr, therefore, appears to be more critical to T h 17 cell development than T reg cell generation. On the other hand, Quintana et al. (21) (20, 35) . IL-22 is a member of the IL-10-related cytokine family and is highly expressed by T h 17 cells. IL-22 −/− mice are less susceptible to CIA than WT mice, indicating that IL-22 is pro-inflammatory (36). Nakahama et al. (30) showed that Ahr −/− mice are resistant to CIA development owing to reduced T h 17 cell differentiation. Interestingly, Ahr deficiency specifically in T cells, but not in macrophages, suppresses the development of CIA. These results suggest that the pro-inflammatory effects of Ahr in mice with CIA are mediated via T h 17 cells and IL-22. IL-22 deficiency, however, enhances the development of inflammatory bowel disease in various models such as T-cell-mediated colitis and DSSinduced colitis (37) . Treating mice with FICZ increases IL-22 levels and protects mice against colitis induced by trinitrobenzenesulfonic acid (TNBS), DSS or T-cell transfer, whereas (39, 40) . Consistent with these findings, bone marrow-derived macrophages from Ahr −/− mice produce increased levels of IL-1β compared with WT cells (40) . A recent study also demonstrated that overproduction of histamine in Ahr −/− peritoneal macrophages drives IL-6 expression (41). Of note, macrophages can be polarized into M1 or M2 cells in response to different stimuli (42) . M1 macrophages produce high levels of pro-inflammatory cytokines, including IL-6, TNF-α and IL-12, to clear bacterial, viral and fungal infections, whereas M2 macrophages produce high levels of IL-10 in response to parasitic infections (42) . Ahr is expressed in both GM-CSF-induced M1 and M-CSF-induced M2 macrophages, whereas Ahr expression is up-regulated by LPS in M1 but not M2 macrophages (our unpublished data). Altered expression of such pro-inflammatory cytokines as IL-6 in macrophages may underlie these Ahr-mediated effects.
Ahr is also involved in NF-κB-related signaling in stimulated macrophages. Ahr interacts with STAT1 on the IL-6 promoter, which suppresses LPS-induced activation of IL-6 expression by inhibiting the transcriptional activity of NF-κB (39) . It is important to note that Ahr plays different roles in CpG-TLR9 and LPS-TLR4 signaling. Ahr is expressed in macrophages in response to CpG but does not regulate the production of pro-inflammatory or anti-inflammatory cytokines in these cells (39) . Kimura et al. (39) demonstrated that LPS and CpG activate STAT1 in macrophages. Binding of Ahr and STAT1, however, has been observed in response to LPS stimulation but not CpG (39) . These results suggest that Ahr does not contribute to CpG signaling in macrophages due to a lack of binding between Ahr and STAT1. LPS may induce the expression of currently unknown factors that are required for Ahr-STAT1 binding, whereas CpG does not. In addition, Gao et al. (43) revealed that, unlike CpG, LPS significantly induces plasminogen activator inhibitor-2 (Pai-2) expression in RAW 264.7 macrophages (22.7-fold increase in expression in response to LPS). Furthermore, Ahr cooperates with Pai-2 to regulate pro-inflammatory cytokine production in macrophages through an LPS-dependent mechanism that involves NF-κB but not Arnt (40) . Therefore, Pai-2 expressed in response to LPS may be one of the undefined factors that are required for Ahr-STAT1 binding. The potential role of Pai-2 in the interaction between Ahr and STAT1 during inflammatory cytokine production should be further investigated.
In humans, macrophages are affected by Ahr activation and the resulting dysregulation of vitamin catabolism. The active form of vitamin D3 regulates immune responses, and vitamin D deficiency contributes to many diseases, including the deleterious effects of cigarette smoking. Matsunawa et al. (44) suggested that BaP-induced vitamin D3 deficiency and Ahr activation in macrophages mediate some of the effects of smoking. Ahr activated by BaP-a polycyclic aromatic hydrocarbon-stimulates vitamin D3 catabolism to modulate vitamin D signaling. Another study of human macrophages showed that Ahr cooperates with the transcription factor cellular viral musculoaponeurotic fibrosarcoma oncogene homolog (c-maf) to control β7-integrin expression in response to BaP (45) . β7-Integrin is a newly identified molecular target of polycyclic aromatic hydrocarbons. Increased β7-integrin expression in response to these environmental contaminants most likely requires activation of cooperative pathways involving AhR and c-maf. β7-Integrin may be a homing receptor on memory and effector cells moving to lamina propria and on naive lymphocytes extravasating in the gut (46) . Therefore, changes in β7-integrin expression in response to polycyclic aromatic hydrocarbons and the downstream Ahr-c-maf interaction may alter immune responses in the gut. In summary, Ahr regulates the inflammatory responses of macrophages by interacting with STAT1, Pai-2 or c-maf.
TLR activation in macrophages and T-cell responses in the CIA model appear to elicit contradictory Ahr activities (30, 39) . Ahr may interact with other factors-e.g. interferon regulatory factor 4 (IRF4)-to affect the function and differentiation of T cells and macrophages. IRF4 plays crucial roles in T h 17 cell and macrophage differentiation. IRF4 is thought to positively regulate the development of several T-cell subsets, including T h 17 cells (47) . In T h 17 cells, IRF4 deficiency reduces the expression of RORγt and RORα, both of which are important for T h 17 cell differentiation (48) . IRF4-deficient mice do not develop EAE, and T h cells from these mice fail to differentiate into T h 17 cells (48) . On the other hand, in macrophages, IRF4 negatively regulates TLR signaling and the production of the pro-inflammatory cytokines TNF-α and IL-12 in response to LPS (49, 50) . Additionally, IRF4 interacts with Jumonji domaincontaining protein 3 to control M2 macrophage polarization (51) . IRF4 has at least two distinct functions in T cells and macrophages, either promoting pro-inflammatory effects via enhanced T h 17 cell development or increasing anti-inflammatory effects by inhibition of pro-inflammatory cytokine production in macrophages or polarizing M2 macrophages. The promoter of IRF4 contains two AhR binding sites. Therefore, Ahr may bind to IRF4 in T cells or macrophages and regulate the function of these cells by affecting T h 17 cell differentiation or macrophage polarization, respectively. An interaction between Ahr and IRF4 may underlie the different regulatory roles of Ahr in T cells and macrophages and in experimental models of inflammatory diseases, such as CIA or endotoxin shock.
Ahr in DCs and anti-inflammatory effects
DCs play key roles in antigen presentation and the initiation of T-cell responses. These antigen-presenting cells can be divided into various subsets based on the expression profiles of phenotypic markers (52) . Naive T-cell activation, proliferation and differentiation are induced by DCs and associated inflammatory cytokines. TCDD can induce Ahr expression and activation in DCs to enhance DC differentiation (53) . In addition to TCDD, the TLR ligands LPS and CpG induce Ahr expression in bone marrow-derived DCs (BMDCs) (54) . In response to LPS or CpG, WT and Ahr −/− BMDCs show similar IL-6 and TNF-α production, whereas IL-10 levels are significantly reduced in Ahr −/− BMDCs (54). In Ahr −/− mice, RelB, a regulator of NF-κB signaling, is rapidly degraded, which may reduce IL-10 production in Ahr −/− BMDCs (55, 56) .
In addition, as yet unidentified factors likely underlie the discrepant results related to Ahr, such as cellular responses to TCDD, FICZ, ITE and tryptophan metabolites. Depending on the ligand, Ahr regulates Foxp3 + Treg and T h 17 cells, resulting in different effects in various experimental disease models. In BMDCs, TCDD and FICZ induce the same phenotypic changes (57) . Recently, Wu et al. (58) showed that a lack of Ahr reduces the expression of LPS-induced inflammatory genes, including CYP1A1, COX-2, CEBPβ and IDO in BMDCs. IDO encodes indoleamine 2,3-dioxygenase, an enzyme that degrades tryptophan into other metabolites (59) . The alternative NF-κB pathway is also linked to the induction of IDO expression in DCs. Kyn-a first-round product of IDO-mediated tryptophan degradation-enhances T reg cell development and inhibits IL-17 production from T h 17 cells (28, 60) . Consistent with these results, Vogel et al. (53) demonstrated that the spleens of TCDD-treated mice show increased and decreased levels of the T reg cell marker Foxp3 in response to induction and inhibition of IDO activity, respectively.
Taken together, these data suggest that Ahr deletion or activation alters the functions of BMDCs in response to various stimuli. Ahr plays important roles in DCs and regulates immune responses to promote or suppress the development of certain experimental and inflammatory diseases, whereas the profiles and effects of Ahr expression and activation in various DC subsets, including myeloid DCs and plasmacytoid DCs, are currently unclear. The regulatory roles of Ahr in the range of DC subsets should be further investigated.
Ahr activation and immunosuppression in B cells
B cells-key components of humoral immunity-are sensitive to such toxic compounds as TCDD. Ahr is an important mediator of the effects of TCDD on B cells (61) . TCDD induces Ahr expression and results in LPS-induced inhibition of IgM secretion in the CH12.LX B-cell line (62) . Changes in B-cell differentiation and antibody production may depend on BTB and CNC homology 2 (Bach2), a direct target of Ahr (63) .
TCDD-mediated suppression of B-cell differentiation into plasma cells involves several transcription factors, including PR domain zinc finger protein 1 (Prdm1), B-cell lymphoma 6 (Bcl6) and paired box protein 5 (Pax5) (64) . Bach2 expression in response to TCDD-Ahr binding or antigen activation inhibits Prdm1 and regulates the suppressive effects of Bcl6 and Pax5 (63) . In addition, Tanaka et al. (65) found that IL-4 causes Ahr expression and activation in B cells. Ahr, however, is not involved in IgE synthesis by B cells (65) , and the regulation of immunoglobulin synthesis requires further investigation. Suppressor of cytokine signaling 2 is dose dependently expressed in response to TCDD in murine B cells (66) .
A lack of Ahr also affects the maturation of B cells from bone marrow. Thurmond et al. (67) demonstrated that Ahr −/− mice have more pro-/pre-B cells than Ahr +/+ mice and TCDD reduces the number of pro-/pre-B cells in Ahr +/+ mice. Interestingly, Ahr affects B cells only during early developmental stages. The precise mechanism by which the Ahr regulates the number of early pro-/pre-B and immature B cells is unclear (67) . TCDD also impairs the effector functions of primary human B cells and suppresses IgM responses in most donors (68) . TCDD activates the Ahr in B cells and impairs B-cell differentiation and IgM production.
We have summarized studies of interactions between Ahr and other downstream molecules in different cell types in Table 2 .
Ahr in other cell types

Skin cells
Ahr is expressed in Langerhans cells, a DC subset that serves as antigen-presenting cells in the epidermis. Ahr −/− Langerhans cells do not mature or function properly, which may contribute to skin allergies (69) . The lack of Ahr prevents the development of invariant epidermal GM-CSFproducing γδ T cells in the skin of mice, which may affect Langerhans cell maturation owing to reduced GM-CSF levels (70) . Furthermore, Ikuta et al. (71) demonstrated that Ahr co-localizes with the transcriptional repressor B lymphocyte maturation protein 1, which is expressed from an Ahr target gene in epidermal keratinocytes and sebocytes. In normal human epidermal keratinocytes, the antifungal agent ketoconazole activates NF erythroid 2-related factor-2 (Nrf2) via AhR signaling (72) . The AhR-Nrf2 pathway may provide a foundation for therapies for inflammatory skin diseases.
Neuroinflammatory and brain tumor cells
Platten et al. (73) suggested treating autoimmune neuroinflammation with the synthetic tryptophan metabolite N- (3,4-dimethoxycinnamoyl) anthranilic acid (3, . Although many Ahr ligands are toxic and cannot be used therapeutically, 3,4-DAA is an orally active compound with favorable pharmacokinetics in humans. Established EAE in mice is ameliorated by 3,4-DAA (73) . Recently, Opitz et al. (74) demonstrated that Kyn is also an endogenous Ahr ligand in humans. Generated by human brain tumor cells via tryptophan-2,3-dioxygenase (TDO), Kyn suppresses antitumor immune responses (74) . Mechanistically, tumors can escape immune responses by expressing IDO or TDO and locally
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depleting tryptophan, which has led to studies of IDO and TDO inhibitors as antitumor therapies (75, 76) .
Cells in the gut
Lee et al. (77) (77, 78) . Moreover, innate lymphoid cells expressing the nuclear receptor RORγt contribute to gut immunity, possibly because of the need for IL-22 (79) . Ahr promotes gut immunity by regulating the function of RORγt + innate lymphoid cells (79) . Additionally, IELs play important roles in intestinal immunity. Li et al. (80) reported that Ahr helps maintain the IEL population; Ahr deficiency reduced the number of IELs, increased the bacterial burden and promoted DSS-induced colitis (80) . Each of these results supports a modulatory role for Ahr in immune responses in the gut.
Bone marrow and stem cells
Sakai et al. (81) found a defect in the long-term reconstitution activity of TCDD-treated hematopoietic stem cells (HSCs) but not in Ahr −/− HSCs. TCDD increased the number and damaged the stem cell functions of CD34 − KSL (CD34 − , c-kit + , Sca-1 + , lineage-negative) cells, whereas an absence of Ahr prevented effects on the stem cell activity of these cells (81) . In this study, the authors hypothesized that TCDD affected the expression of several intrinsic factors that control HSC self-renewal and/or reconstitution activities (81) . In particular, HOXB4 seems to play an important role because an upstream region of the HOXB4 gene contains two XREs that may interact with TCDD-bound Ahr/Arnt (81) . Therefore, Ahr/Arnt may inhibit HOXB4 expression in HSCs (81) . Additionally, Boitano et al. (82) discovered the purine derivative StemRegenin 1 (SR1), which promotes ex vivo expansion of CD34 + cells from primary human HSCs. Interestingly, SR1 is an Ahr antagonist and SR1-induced CD34 + cell proliferation is mediated through direct binding to Ahr (82) . Although the molecular mechanisms underlying the effects of Ahr in HSCs have not been detailed, using SR1 to antagonize the activity of Ahr may improve clinical approaches to HSC-based therapies (82) . Recently, Korkalainen et al. (83) reported that activating Ahr with a low dose of TCDD (10 fM) affected osteoblast and osteoclast differentiation from bone marrow-derived stem cells. TCDD significantly reduces mRNA levels of various factors involved in osteoblast differentiation, including RUNX2, alkaline phosphatase and osteocalcin, and decreases the number of F-actin rings and TRACP + multinucleated cells, both of which are markers of osteoclast differentiation. These results suggest that Ahr contributes to bone quality in animals exposed to TCDD. Bone marrow stromal cells (BMSCs) regulate the growth and development of hematopoietic cell lineages. LPS-stimulated BMSCs produce cytokines, including IL-6 and GM-CSF. Interestingly, TCDD specifically suppresses LPS-induced IL-6 production in BMSCs, suggesting that Ahr agonists regulate BMSCs to trigger inflammatory responses to antigens (84) . Ahr activation in hematopoietic stem/progenitor cells affects cellular trafficking and migration (85, 86) . Tables 1 and 3 provide a summary of studies examining Ahr-mediated effects in various cells and tissues, and the potential functions of Ahr in several autoimmune disease models.
Conclusion
In summary, a number of studies have provided valuable insights into the roles of Ahr in immune responses, including regulating transcription factors, cellular proteins and responses to chemical compounds via the Ahr-Arnt, NF-κB and p38-MAPK signaling pathways. Immune cell-specific conditional knockout mice have been used to examine Ahr in various immune cell types, including macrophages and T cells. Ahr is an anti-inflammatory factor in macrophages, whereas it is likely pro-inflammatory in T cells. Studies of mice bearing specific deletions of Ahr in DCs, B cells or epithelial cells will likely provide additional insights. Furthermore, the ligands of Ahr activate multiple signal transduction pathways. Elucidating the mechanisms by which Ahr regulates immune responses will provide a foundation for therapeutically targeting this molecule in a range of autoimmune and inflammatory diseases. 
